The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
by
, , , , ,
Shehab Mohamed
1,
Luca Bertolaccini
1,*
,
Domenico Galetta
1,2
,
Francesco Petrella
1,2
,
Monica Casiraghi
1,2,
Filippo de Marinis
3 and
Lorenzo Spaggiari
1,2 1
Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
2
Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy
3
Department of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(9), 2476; https://doi.org/10.3390/cancers15092476
Submission received: 22 February 2023
/
Revised: 13 April 2023
/
Accepted: 21 April 2023
/
Published: 26 April 2023
(This article belongs to the Special Issue Advances in Cancer Immunotherapy)
Simple Summary
Surgical resections remain the gold standard for early stages non-small-cell carcinoma (NSCLC) and may be considered for locally advanced tumors. Medical treatment has changed drastically in recent years, especially for advanced stages, for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. The addition of radical surgical resection following immunotherapy or immuno-chemotherapy is feasible and safe with low surgical-related mortality and morbidity in selected patients with initially unresectable NSCLC.
Abstract
Many new treatment modalities for non-small-cell carcinoma (NSCLC) have been described in the last two decades. Surgical resections remain the gold standard for early stages and may be considered for locally advanced tumors. Medical treatment has changed drastically in recent years, especially for advanced stages, for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. The addition of radical surgical resection following immunotherapy or immuno-chemotherapy is feasible and safe with low surgical-related mortality and morbidity in selected patients with initially unresectable NSCLC. However, data from multiple ongoing trials with overall survival as the primary endpoint should be awaited before this strategy is introduced into the standard of care.
Keywords:
lung cancer; immunotherapy; thoracic surgery; review
